Combination treatment may improve survival of breast cancer patients with brain metastases

Combination treatment may improve survival of breast cancer patients with brain metastases

Adding an angiogenesis inhibitor to treatment with a HER2-inhibiting drug could improve outcomes for patients with HER2-positive breast cancer who develop brain metastases. Investigators report the first preclinical study combining antiangiogenic and anti-HER2 drugs in an animal model of brain metastatic breast cancer. View Source